Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Researchers identify six gene loci associated with pulmonary diseases

Researchers identify six gene loci associated with pulmonary diseases

In their investigations or so-called genome-wide association studies, the team of researchers compared the genetic profile of study participants to the forced vital capacity (FVC), a volume parameter of lung function. [More]
No link between consumption of cow's milk-based formula and development of autoantibodies in kids

No link between consumption of cow's milk-based formula and development of autoantibodies in kids

There is no correlation between the consumption of a cow's milk-based formula or hydrolyzed protein formula and the development of diabetes-associated autoantibodies in children younger than seven, according to a worldwide research study published in the Journal of the American Medical Association (JAMA). [More]
New app for smartphones automatically calculates carbohydrate content of meal

New app for smartphones automatically calculates carbohydrate content of meal

An app for smartphones automatically calculates the carbohydrate content of a meal. The programme called "GoCARB" enables diabetics to better plan their meals and to control their blood glucose easier. [More]
Researchers emphasize critical need to utilize multi-pronged approach to treat diabetes mellitus

Researchers emphasize critical need to utilize multi-pronged approach to treat diabetes mellitus

Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University; Marc A. Pfeffer, M.D., Dzau professor of medicine at Harvard Medical School; John W. Newcomer, M.D., executive vice dean of FAU's College of Medicine and interim vice president for research at FAU; Paul S. Jellinger, M.D., affiliate professor at the University of Miami Miller School of Medicine; and Alan Garber, M.D., Ph.D., professor of medicine at Baylor, have published a commentary in the American Journal of Managed Care titled "Treatment of Diabetes Mellitus: The Urgent Need for Multifactorial Interventions." [More]
Patients with diabetes mellitus have worse long-term outcomes following CABG surgery

Patients with diabetes mellitus have worse long-term outcomes following CABG surgery

Patients with diabetes mellitus have worse long-term outcomes and higher associated costs following coronary artery bypass grafting (CABG) surgery than patients without diabetes, according to a study in the June 2014 issue of The Annals of Thoracic Surgery. [More]
Contemporary dataset reveals burden of paediatric pneumococcal disease

Contemporary dataset reveals burden of paediatric pneumococcal disease

Children with chronic or immunocompromising medical conditions continue to be at increased risk for developing pneumococcal disease in the current era of universal immunisation, US researchers report. [More]
Intensive insulin has lasting benefits for diabetic MI survivors

Intensive insulin has lasting benefits for diabetic MI survivors

Patients with diabetes given intensive insulin treatment following an acute myocardial infarction had improved survival over 20 years of follow-up of the DIGAMI 1 trial, report the investigators. [More]
Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain. [More]
5-year survival of diabetic kidney transplant patients now on par with nondiabetic recipients

5-year survival of diabetic kidney transplant patients now on par with nondiabetic recipients

Mayo Clinic researchers have discovered that the five-year survival of diabetic kidney transplant patients is now on par with the five-year survival of nondiabetic kidney recipients. [More]
AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL). [More]
Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control. [More]
Teva's SYNRIBO for injection receives FDA approval for home administration

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use. [More]
Severe diabetes linked to brain atrophy

Severe diabetes linked to brain atrophy

Type 2 diabetes may be associated with brain degeneration, according to a new multicenter study published online in the journal Radiology. The study also found that, contrary to common clinical belief, diabetes may not be directly associated with small vessel ischemic disease, where the brain does not receive enough oxygenated blood. [More]
GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GlaxoSmithKline plc and Theravance, Inc. today announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies in the US. [More]
European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

European Commission approves VOKANAMET for treatment of adults with type 2 diabetes mellitus

Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved VOKANAMET® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control. [More]
FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]
Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Two new studies presented today at the International Liver CongressTM 2014 have provided more evidence to clarify the role of non-alcoholic fatty liver disease (NAFLD) as an independent risk factor for the development of cardiovascular disease (CVD). [More]
Continuous glucose monitoring in children: an interview with Terrance Gregg, CEO of Dexcom

Continuous glucose monitoring in children: an interview with Terrance Gregg, CEO of Dexcom

Scientific research into CGM-like sensors goes back more than 40 years. I was working with the first company to begin commercial development, MiniMed, back in 1992 when the science was really beginning to percolate. In 1999 the FDA approved the first CGM device for use in the United States. [More]
Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Takeda Pharmaceuticals Company Limited will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology’s 63rd Annual Scientific Session in Washington, DC. [More]
Expert highlights the importance of gender-specific approach for treating diabetes mellitus

Expert highlights the importance of gender-specific approach for treating diabetes mellitus

The international guidelines on the drug-based therapy of diabetes mellitus specify which factors need to be taken into account during treatment. [More]